Our collective commitment to fundraising and dedicated research serves as a beacon of light in the journey towards discovering effective treatments and, ultimately, a cure for this rare genetic disorder.

The Ara Parseghian Medical Research Fund has been at the forefront of combating Niemann-Pick Type C disease and our success and impact are due to the partnerships with NPC families, donors, researchers, and companies.

Families affected by Niemann-Pick Type C have found a vital source of support and collaboration in the Ara Parseghian Medical Research Fund. The Parseghian Fund serves as a dedicated partner to these families, offering not only hope but also a sense of community and shared purpose. Through their active involvement with the fund, NPC families contribute their firsthand experiences, insights, and determination to accelerate research efforts. They engage in fundraising activities, awareness campaigns, and advocacy initiatives, working hand in hand with the Parseghian Fund to raise both funds and awareness about NPC disease. This collaborative spirit empowers these families, allowing them to play an essential role in advancing research, and ultimately, in the quest for effective treatments and a cure for NPC disease.

One of the most critical aspects of APMRF's work is its collaboration with our supporters. The fund relies heavily on the generosity of individuals, families, and organizations who share a common goal: finding a cure for NPC disease. These donors provide essential financial support, which allows APMRF to carry out its research initiatives and support affected families.

APMRF actively seeks partnerships with leading researchers in the field of NPC disease and neurodegenerative disorders. By collaborating with established scientists and institutions, the fund can tap into a wealth of expertise and resources.

APMRF also forms strategic partnerships with biotech and pharmaceutical companies. These collaborations are pivotal in translating scientific discoveries into viable therapies. By working with industry leaders, the fund can access cutting-edge technologies, drug development expertise, and clinical trial capabilities.